Pfizer (PFE) Long-Term Deferred Tax (2009 - 2026)

Pfizer has disclosed Long-Term Deferred Tax across 18 years of filings, most recently posting $10.0 billion for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 4.43% year-over-year to $10.0 billion; the TTM figure through Mar 2026 stood at $10.0 billion (up 4.43% YoY), while the FY2025 annual figure was $9.7 billion, up 11.97% from the prior year.
• Long-Term Deferred Tax grew to $10.0 billion in Q1 2026, from $9.7 billion in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for PFE reached as high as $11.0 billion in Q3 2025 and fell as low as $3.7 billion in Q4 2023.
• The 5-year median for Long-Term Deferred Tax is $7.9 billion (2024), against an average of $7.9 billion.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax jumped 159.91% — and 2023, when it sank 44.63%.
• A 5-year view of Long-Term Deferred Tax shows it stood at $6.7 billion in 2022, then slumped by 44.63% to $3.7 billion in 2023, then surged by 133.73% to $8.7 billion in 2024, then rose by 11.97% to $9.7 billion in 2025, then rose by 2.74% to $10.0 billion in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $10.0 billion, $9.7 billion, and $11.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.